Top Markets
Coin of the day
WPD Pharmaceuticals Inc. WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc.

WBIO
Kedudukan dalam Saham #34463
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver,... WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
Harga Saham
$0.04895618
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$5.55M
Perubahan (1 hari)
-0.04%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan WPD Pharmaceuticals Inc. (WBIO)

Kategori

Pendapatan untuk WPD Pharmaceuticals Inc. (WBIO)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini WPD Pharmaceuticals Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi WPD Pharmaceuticals Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE